A 13-trial review maps early analgesia options in acute pancreatitis, highlighting evidence to support treatment decisions. https://www.mattheneus.com/editorial/pubmed-acute-pancreatitis-early-analgesia-randomised-trials-2026-10-01 #HTA #EvidenceSynthesis #HealthEconomics

WINTER HESG 2027 – FINAL CALL FOR ABSTRACTS – CLOSES TODAY (05/10/26) AT 5PM #healtheconomics

Australia aligns Fabry disease enzyme therapies under one PBS reimbursement pathway. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/pbac-agalsidase-alfa-beta-fabry-pbs-switching-framework-2026-07

Heart failure affects 56 million people worldwide, but budget impact depends on the local etiologic mix. https://www.mattheneus.com/editorial/global-heart-failure-burden-local-budget-impact-denominator-2026-09-30 #HTA #HealthEconomics #RWE

Thailand's access threshold for luspatercept points to a required 90.5% price reduction. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/thailand-luspatercept-price-threshold-budget-impact-2026-09-28

Australia’s PBAC backs subcutaneous amivantamab at IV price parity, highlighting the HTA role of formulation bridging.

https://www.mattheneus.com/editorial/pbac-amivantamab-subcutaneous-exon20-lung-cancer-formulation-bridge-2026-07

#HTA #Pharma #HealthEconomics

Korea's 100-day listing pathway puts post-launch evidence planning at the centre of durable value decisions. https://www.mattheneus.com/editorial/korea-100-day-listing-post-launch-value-evidence-plan-2026-10-04 #HTA #RWE #HealthEconomics

A Dutch reimbursement verdict turns on a price cut above 53% and a MAIC-based evidence case. https://www.mattheneus.com/editorial/zin-enhertu-her2-mutated-nsclc-price-cut-maic-2026-09-22 #HTA #MAIC #HealthEconomics #Pharma

Poland questions stand-alone nurse-led chronic wound care in its current design.

https://www.mattheneus.com/editorial/aotmit-nurse-led-chronic-wound-service-coverage-position-2026-09-28

#HTA #EvidenceSynthesis #HealthEconomics

Long-term follow-up strengthens the value case for outpatient labour induction.

https://www.mattheneus.com/editorial/outpatient-labour-induction-long-term-outcomes-cost-effectiveness-2026-10-03

#HTA #HealthEconomics #RWE

Specialised formula access expands for pyridoxine-dependent epilepsy.

https://www.mattheneus.com/editorial/pbac-ga1-anamix-pyridoxine-dependent-epilepsy-restricted-benefit-2026-07

#HTA #EvidenceSynthesis #HealthEconomics

AOTMiT recommends against Akeega reimbursement in metastatic prostate cancer, citing comparator uncertainty. https://www.mattheneus.com/editorial/aotmit-akeega-mhspc-negative-reimbursement-amplitude-comparator-uncertainty-2026-09-29 #HTA #HealthEconomics

Goal Attainment Scaling needs a documented implementation record before it can support credible payer evidence. https://www.mattheneus.com/editorial/goal-attainment-scaling-implementation-record-payer-evidence-2026-10-04 #HTA #EvidenceSynthesis #HealthEconomics

AI screening for retinopathy of prematurity kept its modelled value until rural coverage fell to 11%, exposing a critical implementation threshold. https://www.mattheneus.com/editorial/ai-retinopathy-prematurity-screening-rural-coverage-cost-effectiveness-2026-10-02 #HTA #HealthEconomics #RWE

Australia grants brivaracetam oral solution a formulation-specific pricing exemption, separating its pricing treatment from other forms. https://www.mattheneus.com/editorial/pbac-brivaracetam-oral-solution-section84ah-price-exemption-2026-10-01 #HTA #Pharma #HealthEconomics

Australia expands access to metabolic formulas for ECHS1 and HIBCH deficiencies, widening support for two rare disorders. https://www.mattheneus.com/editorial/pbac-echs1-hibch-metabolic-formula-listing-extension-2026-07 #HTA #HealthEconomics #Pharma

Germany's proposed evidence-potential route could reshape how high-need medicines enter AMNOG assessment. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/g-ba-amnog-reform-qualitative-potential-evidence-route-2026-09-23

NICE moves fourth-line isatuximab into routine myeloma care, with SACT data shaping the comparator story. https://www.mattheneus.com/editorial/nice-ta1194-isatuximab-fourth-line-myeloma-sact-comparator-2026-09-24 #HTA #HealthEconomics #RWE

Germany and Switzerland place cybersecurity responsibility at different points in digital-health reimbursement. https://www.mattheneus.com/editorial/digital-health-cybersecurity-reimbursement-responsibility-germany-switzerland-2026-10-01 #HTA #HealthEconomics #RegulatoryAffairs

Universal malaria testing could save the US blood supply $13.6M in year one. https://www.mattheneus.com/editorial/universal-malaria-nat-screening-us-blood-supply-budget-impact-2026-10-01 #HTA #HealthEconomics #RWE